



## **Verrica Pharmaceuticals to Present at Upcoming Investor Conferences**

WEST CHESTER, PA – May 9, 2024 (GLOBE NEWSWIRE) – Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Ted White, Verrica Pharmaceuticals’ President and Chief Executive Officer, will present at the following investor conferences:

### **RBC Capital Markets Global Healthcare Conference**

Date: Wednesday, May 15, 2024

Time: 3:05 p.m. ET

Location: New York, NY

### **HCW BioConnect Conference**

Date: Monday, May 20, 2024

Time: 10:00 a.m. ET

Location: New York, NY

The webcasts can be accessed in the Investors/Presentations & Events section of the Verrica website at [www.verrica.com](http://www.verrica.com) and will be available for 90 days following the event.

### **About Verrica Pharmaceuticals Inc.**

Verrica is a dermatology therapeutics company developing medications for skin diseases requiring medical interventions. On July 21, 2023, YCANTH<sup>®</sup> (cantharidin), became the first treatment approved by the FDA to treat adult and pediatric patients two years of age and older with molluscum contagiosum, a highly contagious viral skin infection affecting approximately 6 million people in the United States, primarily children. YCANTH (VP-102) is also in development to treat common warts and external genital warts, two of the largest remaining unmet needs in medical dermatology. Verrica is also developing VP-103, its second cantharidin-based product candidate, for the treatment of plantar warts. Verrica has also entered a worldwide license agreement with Lytix Biopharma AS to develop and commercialize VP-315 (formerly LTX-315 and VP-LTX-315) for non-melanoma skin cancers including basal cell carcinoma and squamous cell carcinoma. For more information, visit [www.verrica.com](http://www.verrica.com).

### **FOR MORE INFORMATION, PLEASE CONTACT:**

Investors:

**Terry Kohler**

Chief Financial Officer

[tkohler@verrica.com](mailto:tkohler@verrica.com)

**Kevin Gardner**

LifeSci Advisors

[kgardner@lifesciadvisors.com](mailto:kgardner@lifesciadvisors.com)

**Chris Calabrese**

LifeSci Advisors

[ccalabrese@lifesciadvisors.com](mailto:ccalabrese@lifesciadvisors.com)